Terns Pharmaceuticals (TERN) News Today → Shocking: One AI startup's revenue could surge 4,735% (From Manward Press) (Ad) Free TERN Stock Alerts $5.90 -0.24 (-3.91%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 2:16 AM | americanbankingnews.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Rating of "Moderate Buy" by AnalystsMay 17 at 4:05 PM | globenewswire.comTerns Pharmaceuticals to Participate in UBS Obesity Therapeutics DayMay 16, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Issued By HC WainwrightMay 16, 2024 | marketbeat.comRussell Investments Group Ltd. Invests $1.80 Million in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Russell Investments Group Ltd. acquired a new position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 277,741 shares of the company's stock, valMay 16, 2024 | americanbankingnews.comTerns Pharmaceuticals (NASDAQ:TERN) Rating Reiterated by HC WainwrightMay 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and OptimizeRx (OPRX)May 14, 2024 | markets.businessinsider.comHold Rating on Terns Pharmaceuticals Pending Clinical Trial OutcomesMay 14, 2024 | marketbeat.comHC Wainwright Reaffirms "Neutral" Rating for Terns Pharmaceuticals (NASDAQ:TERN)HC Wainwright reissued a "neutral" rating and set a $5.50 price target on shares of Terns Pharmaceuticals in a research report on Tuesday.May 13, 2024 | finanznachrichten.deTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 13, 2024 | finance.yahoo.comTerns Pharmaceuticals Inc (TERN) Q1 2024 Earnings: Misses Analyst Net Loss ProjectionsMay 13, 2024 | globenewswire.comTerns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 8, 2024 | globenewswire.comTerns Pharmaceuticals Announces Leadership ChangesMay 7, 2024 | globenewswire.comTerns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024May 3, 2024 | globenewswire.comTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)April 30, 2024 | marketbeat.comTerns Pharmaceuticals' (TERN) Neutral Rating Reiterated at HC WainwrightHC Wainwright reissued a "neutral" rating and set a $5.50 price target on shares of Terns Pharmaceuticals in a research report on Tuesday.April 30, 2024 | markets.businessinsider.comBuy Rating Reiterated for ARQT Amidst Strong Zoryve Performance and Market ResilienceApril 29, 2024 | globenewswire.comTerns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive DifferentiationApril 26, 2024 | markets.businessinsider.comOptimistic Buy Rating for Terns Pharmaceuticals Based on TERN-701 Market Potential and StrategyApril 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: AstraZeneca (AZN) and BioMarin Pharmaceutical (BMRN)April 18, 2024 | morningstar.comTerns Pharmaceuticals Inc Ordinary SharesApril 11, 2024 | finanznachrichten.deTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business OfficerApril 10, 2024 | globenewswire.comTerns Pharmaceuticals Appoints Melita Sun Jung as Chief Business OfficerApril 9, 2024 | msn.comMadrigal announces US launch of NASH/MASH drug RezdiffraApril 5, 2024 | investing.comVivo Capital entities sell Terns Pharmaceuticals shares worth $2.8 millionApril 5, 2024 | insidertrades.comVivo Opportunity, Llc Sells 138,066 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) StockApril 4, 2024 | insidertrades.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Major Shareholder Vivo Opportunity, Llc Sells 181,117 SharesMarch 30, 2024 | morningstar.comThis small-cap stock is expected to take off - if its weight-loss pill trial succeedsMarch 28, 2024 | marketwatch.comThis small-cap stock is expected to take off — if its weight-loss pill trial succeedsMarch 27, 2024 | marketbeat.comUBS Group Lowers Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $18.00UBS Group lowered their price objective on shares of Terns Pharmaceuticals from $19.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday.March 27, 2024 | msn.comHere’s Why Ozempic And Mounjaro Rivals Won’t Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime SoonMarch 25, 2024 | investorplace.comWall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy RichMarch 21, 2024 | markets.businessinsider.comOptimistic Buy Rating for Terns Pharmaceuticals Based on Strong Clinical Pipeline and Financial StabilityMarch 18, 2024 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) PT Raised to $19.00BMO Capital Markets lifted their price target on Terns Pharmaceuticals from $18.00 to $19.00 and gave the company an "outperform" rating in a report on Friday.March 18, 2024 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) PT Lowered to $15.00JMP Securities cut their price target on Terns Pharmaceuticals from $17.00 to $15.00 and set an "outperform" rating for the company in a research note on Monday.March 16, 2024 | finance.yahoo.comTERN Apr 2024 15.000 callMarch 14, 2024 | globenewswire.comTerns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesMarch 12, 2024 | finanznachrichten.deTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid LeukemiaMarch 11, 2024 | globenewswire.comTerns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid LeukemiaMarch 7, 2024 | globenewswire.comTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)March 4, 2024 | marketbeat.comFmr LLC Sells 1,932,296 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Fmr LLC decreased its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 27.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,118,050 shares of the company's stock after selling 1,932,296March 3, 2024 | marketbeat.comAcuta Capital Partners LLC Lowers Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Acuta Capital Partners LLC lessened its position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 42.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 555,260 shares of the company's stock after selMarch 1, 2024 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Holdings Lifted by Braidwell LPBraidwell LP raised its stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 54.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,840,052 shares of the company's stock after buying an additional 997,700 shares during theFebruary 29, 2024 | marketbeat.comBarclays PLC Decreases Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Barclays PLC reduced its position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 79.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,327 shares of the company's stockFebruary 27, 2024 | globenewswire.comTerns Pharmaceuticals to Participate in Upcoming March Investor ConferencesFebruary 18, 2024 | marketbeat.comSilverarc Capital Management LLC Trims Stock Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Silverarc Capital Management LLC decreased its position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 16.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 500,000 shares of the comFebruary 16, 2024 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Trading Up 10%Terns Pharmaceuticals (NASDAQ:TERN) Shares Up 10%February 10, 2024 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven brokerages that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and five haveFebruary 9, 2024 | finanznachrichten.deTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)February 7, 2024 | finanznachrichten.deTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive OfficerFebruary 7, 2024 | finance.yahoo.comTerns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4) Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address Global crypto currency reset (41 major banks signed up) (Ad)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. TERN Media Mentions By Week TERN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TERN News Sentiment▼0.540.42▲Average Medical News Sentiment TERN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TERN Articles This Week▼152▲TERN Articles Average Week Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Alto Neuroscience News Today Organogenesis News Today Amarin News Today Korro Bio News Today Verrica Pharmaceuticals News Today Shattuck Labs News Today Neurogene News Today FibroBiologics News Today Revance Therapeutics News Today Esperion Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TERN) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
